About Us
Fresenius Kabi Global at a glance
Our product portfolio comprises of a comprehensive range of IV generic medicines, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems.
Fresenius Kabi employs about 35,000 people worldwide.
With our corporate philosophy of "caring for life", we are committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
In 2017, the company reported sales of more than €6.3 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA health care group.
Key Figures
€ in millions |
2017 |
2016 |
Change |
|---|---|---|---|
| Sales | 6,358 | 6,007 | 6 % |
| EBITDA1 | 1,483 | 1,468 | 1 % |
| Adjusted EBIT2 | 1,237 | 1,171 | 6 % |
| Adjusted Net Income3,4 | 745 | 675 | 10 % |
| Employees | 36,380 | 34,917 | 4 % |
1 Before special terms
2 Consistent with scope of original guidance: before acquisition-related expenses and expenditure for further development of biosimilars business
3 Net income attributable to shareholders of Fresenius Kabi SE & Co. KGaA
4 Consistent with scope of original guidance: before acquisition-related expenses, expenditures for further development of biosimilars business and book gain from U.S. tax reform
